Abstract: The present invention provides a method for manufacturing diamond, comprising electrolytically reducing carbon dioxide into diamond to obtain diamond in an electrolytic reduction apparatus having an anode, a cathode, and an electrolytic solution containing carbon dioxide, wherein the electrolytic solution comprises an ionic liquid.

Abstract: A multi-screw kneader is configured to exhibit an extensional flow function before and behind holes of a disk-shaped segment and a method for producing a nano-composite uses the multi-screw kneader. The multi-screw kneader includes a plurality of kneading screws and the disk-shaped segment in a barrel. The disk-shaped segment partitions the inside of the barrel downstream of a part for supplying a kneading material and includes shaft receiving parts through which rotating shafts of the kneading screws are to rotatably pass and the holes are defined in a periphery of the shaft penetrating parts and are configured to serve as flow channels of the kneading material. The method for producing the nano-composite includes charging nanoparticles as a resin additive using the multi-screw kneader.

Abstract: The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (?4?1?1), laminin 511 (?5?1?1), laminin 521 (?5?2?1), or fragments of these.

Abstract: A gold-supported carbon catalyst includes gold fine particles supported on carbon black, wherein the gold fine particles are coordinated by an alkanethiol at a coverage of from 10% to 70%, and wherein the gold fine particles have an average particle diameter of from 1.0 nm to 1.5 nm.

Abstract: The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing.

Abstract: An electrode used for oxygen reactions, the electrode being excellent in catalytic activity and stability, a method of producing the electrode, and an electrochemical device using the electrode are provided. This electrode includes, as an oxygen catalyst, an oxide that has peaks at positions of 2?=34.88°±1.00°, 50.20°±1.00°, and 59.65°±1.00° in an X-ray diffraction measurement using a CuK? ray and has constituent elements of bismuth, ruthenium, sodium, and oxygen.

Abstract: A method for manufacturing carbon monoxide or an organic compound, which includes electrolytically reducing carbon dioxide to obtain carbon monoxide or an organic compound in an electrolytic reduction apparatus having an anode, a cathode, and an electrolytic solution containing carbon dioxide. Carbon dioxide is selectively reduced into carbon monoxide or a specific organic compound by a potential to be applied to between the anode and the cathode.

Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.

Abstract: In a case where an alkali aqueous solution is used as an electrolyte, provided are an oxygen catalyst excellent in catalytic activity and composition stability, an electrode having high activity and stability using this oxygen catalyst, and an electrochemical measurement method that can evaluate the catalytic activity of the oxygen catalyst alone. The oxygen catalyst is an oxide having peaks at positions of 2?=30.07°±1.00°, 34.88°±1.00°, 50.20°±1.00°, and 59.65°±1.00° in an X-ray diffraction measurement using a CuK? ray, and having constituent elements of bismuth, ruthenium, sodium, and oxygen. An atom ratio O/Bi of oxygen to bismuth and an atom ratio O/Ru of oxygen to ruthenium are both more than 3.5.

Abstract: A wireless receiving apparatus generates an N?×B? weight matrix W whose columns are orthogonal to each other by decomposing an estimated N?×M? channel matrix into the N?×B? weight matrix W and a B?×M? matrix containing two or more non-zero matrix elements in each column, where B? is an integer less than or equal to N?-1 and greater than or equal to M?. Alternatively, the wireless receiving apparatus generates a combination of an N?×B? sub-weight matrix W1 and at least one second sub-weight matrix, where the product of the sub-weight matrix W1 with the at least one second sub-weight matrix is equal to the weight matrix W. The wireless receiving apparatus performs receive beamforming on received signals of N? receiving antennas using the weight matrix W or the sub-weight matrix W1. The wireless receiving apparatus then performs a BP algorithm using receive-beamformed signals.

Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.

Abstract: S100A8-inhibiting peptides include (A) a peptide of 5 to 10 residues in length containing a fifth alanine (Ala) from an N-terminus in an amino acid sequence of SEQ ID NO: 1, or (B) a peptide consisting of an amino acid sequence of SEQ ID NO: 2.

Abstract: In a case where an alkali aqueous solution is used as an electrolyte, provided are an oxygen catalyst excellent in catalytic activity and composition stability, an electrode having high activity and stability using this oxygen catalyst, and an electrochemical measurement method that can evaluate the catalytic activity of the oxygen catalyst alone. The oxygen catalyst is an oxide having peaks at positions of 2?=30.07°±1.00°, 34.88°±1.00°, 50.20°±1.00°, and 59.65°±1.00° in an X-ray diffraction measurement using a CuK? ray, and having constituent elements of bismuth, ruthenium, sodium, and oxygen. An atom ratio O/Bi of oxygen to bismuth and an atom ratio O/Ru of oxygen to ruthenium are both more than 3.5.

Abstract: Provided is a metal negative electrode used for a secondary battery. The metal negative electrode includes an active material portion, a current collector, and a non-electronically conductive reaction space divider. The active material portion forms metal during charging and forms an oxidation product of the metal during discharging. The metal is used as a negative-electrode active material. The current collector is electrically connected to the active material portion. The non-electronically conductive reaction space divider is integrally formed with or connected to the current collector and/or the active material portion. The reaction space divider has a plurality of electrolyte holder portions configured to hold a liquid electrolyte.

Abstract: The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (?5?1?1), laminin 521 (?5?2?1), or a fragment of these.

Abstract: A computer system includes at least one memory and at least one processor coupled to the at least one memory and configured to execute one or more sets of instructions. The one or more sets of instructions, when executed by the at least one processor, cause the computer system to provide virtualized radio access network functions including executing a BP algorithm and provide controller functions including adjusting the total number of iterations of the BP algorithm depending on available computing resources of the computer system.

Abstract: There are provided a method for predicting a springback amount and a method for bending a deformed reinforcing bar including: supplying the deformed reinforcing bar bending the supplied deformed reinforcing bar, and subsequently measuring a first bending angle in a state of releasing a bending force on the deformed reinforcing bar; further bending the reinforcing bar from which the bending force has been released, and subsequently measuring a second bending angle in a state of releasing the bending force; and predicting a relationship between the bending angle and the springback amount by using the measurement results after executing the further bending once or a plurality of times, in which the bending angle is greater for subsequent steps.

Abstract: A wireless receiving apparatus generates an N?×B? weight matrix W whose columns are orthogonal to each other by decomposing an estimated N?×M? channel matrix into the N?×B? weight matrix W and a B?×M? matrix containing two or more non-zero matrix elements in each column, where B? is an integer less than or equal to N?-1 and greater than or equal to M?. Alternatively, the wireless receiving apparatus generates a combination of an N?×B? sub-weight matrix W1 and at least one second sub-weight matrix, where the product of the sub-weight matrix W1 with the at least one second sub-weight matrix is equal to the weight matrix W. The wireless receiving apparatus performs receive beamforming on received signals of N? receiving antennas using the weight matrix W or the sub-weight matrix W1. The wireless receiving apparatus then performs a BP algorithm using receive-beamformed signals.

Abstract: A method implemented in a computer system includes training a network, which is obtained by unfolding an iterative algorithm for demodulation or demodulation and decoding, using a machine learning technique with a loss function that takes into account non-Gaussianity of a log-likelihood ratio (LLR) distribution calculated from an output of the network. The method further includes producing a first set of learned parameters of that iterative algorithm.

Abstract: Provided is a medicament or a method for treating or preventing a corneal endothelial condition, disorder or disease due to a transforming growth factor-? (TGF-?) signal in corneal endothelial cells using a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative. In a preferred embodiment, the corneal endothelial condition, disorder or disease due to the TGF-? signal is Fuchs' corneal endothelial dystrophy.